Phaseline

Companies › Mundipharma Research

Mundipharma Research: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Infectious disease, Respiratory; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rezafungin Acetate
1,3-beta-D-glucan synthase inhibitor
FKS1Phase 2Pneumocystis Pneumonia; Chronic Pulmonary AspergillosisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05835479Rezafungin AcetatePhase 2Pneumocystis PneumoniaRespiratoryMay 2025
NCT06794554Rezafungin AcetatePhase 2Chronic Pulmonary AspergillosisInfectious diseaseNov 2026

Targets

FKS1 (1)

Companies with the same targets

Basilea Pharmaceutica

Companies built like this

Thirty Respiratory Joincare Pharmaceutical Group Industry Shanghai Yidian Pharmaceutical Technology Development Materia Medica Holding Hyundai Bioscience

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.